A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

NEW YORK – Chinese regulatory officials have approved the BRAF inhibitor Braftovi (encorafenib) in combination with Eli Lilly's EGFR-targeted monoclonal antibody Erbitux (cetuximab) for treating ...

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

NEW YORK – The US Food and Drug Administration this week approved a new dosing schedule for Eli Lilly's anti-amyloid Alzheimer's disease drug Kisunla (donanemab), which the company said improves the ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – Radiopharmaceutical company Nuclidium has raised $99 million in Series B financing to advance its copper-61 and copper-67 theranostics, the firm announced Thursday. The round was led by ...